Home / Business and Economy / Danaher Stock: Buy Signal Ahead?
Danaher Stock: Buy Signal Ahead?
4 Jul
Summary
- Danaher Corp. (DHR) to report Q2 2026 earnings on July 21.
- Analysts expect DHR to surpass EPS estimates for the fifth quarter.
- Stock has underperformed S&P 500 and XLV in the past year.
Danaher Corporation, a life sciences and diagnostics innovator, is scheduled to release its fiscal second-quarter 2026 earnings before the market opens on Tuesday, July 21. Analysts project a diluted earnings per share of $1.83, a slight increase from the $1.80 reported in the same quarter last year. This figure aligns with the company's recent performance, having beaten earnings per share (EPS) estimates for the preceding four consecutive quarters.
For the full fiscal year 2026, analysts forecast EPS to reach $8.44, an 8.2% rise from fiscal 2025. Looking ahead to fiscal 2027, EPS is expected to grow to $9.12. Despite these positive projections, Danaher's stock has lagged behind the S&P 500 and the Health Care Select Sector SPDR ETF over the last 52 weeks, with its shares decreasing by 2.3%. In its most recent Q1 report on April 21, DHR's adjusted EPS of $2.06 surpassed expectations, though revenue fell slightly short.
